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ABSTRACT
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired immune-mediated in-
flammatory disorder that targets the myelin sheaths of the peripheral nervous system. Intravenous immunoglobulin (IVIg) 
is a blood product containing immunoglobulin G pooled from many human donors. In fall 2008, CIDP became an approved 
indication for IVIg in the United States and Canada.  
Objective: To evaluate the clinical effectiveness and safety of IVIg for the treatment of CIDP through a systematic review 
of published randomized controlled trials.
Methods: We searched the MEDLINE (1950–2009, including in-process and other non-indexed citations), Embase (1980–
2009) and other databases through the Ovid interface. We applied a methodological filter to limit retrieval to controlled 
clinical trials, meta-analyses and systematic reviews, and health technology assessments. Retrieval was limited to studies 
involving humans, and no language restrictions were employed. We pooled extracted data to estimate the effect size of IVIg 
treatment based on the random-effects model. 
Results: We identified 9 unique randomized controlled trials. Of these, 3 compared IVIg therapy with an active comparator 
(plasma exchange, plasma exchange using extracorporeal immunoadsorption, oral prednisolone, respectively); the other 6 tri-
als had placebo controls. No incremental benefit was seen in terms of primary outcomes for comparisons of IVIg therapy and 
an active comparator. Data from 4 of the 6 placebo-controlled trials were included in a meta-analysis. A significant improve-
ment in disability (i.e., reduction in disability score) was found, with a standardized mean difference of 0.65 (95% confidence 
interval [CI] 0.23 to 1.08) in favour of IVIg. A pooled analysis of the proportion of patients with a response to treatment, as 
defined by the investigators of each of the trials, resulted in a risk ratio of 2.74 (95% CI 1.80 to 4.15) favouring IVIg. 
Interpretation: IVIg therapy was statistically superior to placebo in reducing disability and impairment among patients 
with CIDP. The effectiveness of IVIg was similar to that of the alternative treatment strategies of plasma exchange and oral 
prednisolone 
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hronic  inflammatory  demyelinating  polyradicu-
loneuropathy  (CIDP)  is  an  acquired  immune-
mediated inflammatory disorder that targets the 
myelin  sheaths  of  the  peripheral  nervous  system.  The 
motor weakness symptoms of CIDP resemble those of the 
Guillain–Barré syndrome, but the 2 disorders are arbi-
trarily differentiated by the time to maximum deficit.1 
Patients with CIDP reach maximum clinical deficit about 
8 weeks or more after the onset of symptoms, whereas 
patients with Guillain–Barré syndrome reach maximum 
deficit  within  3–4  weeks.  In  addition,  Guillain–Barré 
syndrome is a self-limited, monophasic illness, whereas 
CIDP has a prolonged course over months to years, which 
may be steadily progressive or relapsing–remitting.2 
Given  the  ambiguities  of  diagnosing  CIDP,  the  true 
prevalence of the disease may be underestimated or over-
estimated. Reported mean prevalence estimates from 6 
studies ranged from 0.46 to 7.7 per 100 000 population.3–8 
Reported prevalence estimates vary by age and sex, the 
highest estimates of 3.12, 9.47 and 19.24 per 100 000 
population having been reported for men 55 years of age 
and older,8 70–79 years of age4 and 80 years of age and 
older,6 respectively. Regional differences within the same 
country have also been reported.3,5 Prevalence and inci-
dence rates have not been reported for Canada, but it can 
be assumed that rates for this country will fall within the 
ranges reported in trials from other countries with simi-
lar  demographic  characteristics,  such  as  England5  and 
Australia:4 1.0–1.9 per 100 000 population.
Patients  with  CIDP  have  shown  improvement  after 
treatment with corticosteroids or plasma exchange,9,10 but 
both therapies have disadvantages. Because of the chronic 
nature of the disease, long-term use of corticosteroids is 
usually required, which carries the risk of numerous ad-
verse events, some of which may be serious.11 The benefit 
of plasma exchange is typically transient, and it is there-
fore  usually  employed  concomitantly  with  some  other 
form of therapy.10 Plasma exchange is also associated with 
several adverse effects, including anaphylactic reactions, 
cardiac  arrhythmias  and  death.12  Furthermore,  plasma 
exchange must be carried out in specialized centres, and 
the repeated procedures require good vascular access.13 
Intravenous immunoglobulin (IVIg) is a blood prod-
uct containing immunoglobulin G pooled from many hu-
man donors. In fall 2008, both the US Food and Drug 
Administration14  and  the  Health  Products  and  Food 
Branch  of  Health  Canada15  granted  Talecris  Biothera-
peutics supplemental licences for its IVIg product to in-
clude CIDP as an indication.
The objective of this systematic review of published 
randomized controlled trials (RCTs) was to evaluate the 
clinical effectiveness and safety of IVIg for the treatment 
of CIDP. 
Methods
Protocol. A protocol was written a priori and was fol-
lowed  throughout  the  review  process.  A  copy  of  the 
protocol was filed with the Canadian Agency for Drugs 
and  Technologies  in  Health  (CADTH).  The  original 
protocol defined the population of interest as adults 18 
years of age or older. However, there was no valid ration-
ale to limit the search to adults, and this age limit was 
subsequently removed.
Sources of information. An unpublished CADTH tech-
nology  report16  served  as  the  starting  point  for  this 
research. To update the original search used in the un-
published report, we undertook a systematic search to 
locate relevant clinical trials, meta-analyses, systematic 
reviews and health technology assessments evaluating 
IVIg for CIDP. The search strategy was developed by an 
information specialist (KC), with input from the project 
team. Before the search strategy was executed, it under-
went peer review by a CADTH information specialist. All 
search results were imported into a Reference Manager 
version 11 database for the purposes of removing dupli-
cates and screening the titles and abstracts. 
We  searched  the  following  bibliographic  databases 
through the Ovid interface: MEDLINE (1996 to 2009, in-
cluding in-process and other non-indexed citations), Em-
base (1996 to 2009) and CINAHL (1982 to 2009). Parallel 
searches were run in PubMed (for non-MEDLINE records 
only), Wiley’s Cochrane Library (Cochrane Database of 
Systematic Reviews,  Database of Abstracts of Reviews 
of Effects, Cochrane Central Register of Controlled Trials 
[CENTRAL], Cochrane Methodology Register and Health 
Technology Assessment Database) and Thomson’s BIOSIS 
Previews (1995 to 2009).
A search strategy with controlled vocabulary and key-
words focusing on the concepts of “CIDP” and “IVIg” was 
executed.
A methodological filter was applied to limit retrieval 
to  controlled  clinical  trials,  meta-analyses,  systematic 
reviews  and  health  technology  assessments.  Further-
more, retrieval was limited to articles with a database 
entry date of December 2007 to 2009 (when possible) 
or a publication date in 2007 or 2008 and to studies of 
the human population (the latter criterion could be ap-
plied  only  within  the  Ovid  interface  and  was  applied 
only to the search for controlled clinical trials). No lan-
guage restrictions were employed. An attempt was made 
to translate all relevant articles published in languages 
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other than English, but translation was limited to the 
capabilities of available staff to translate from French, 
German and Chinese. See online Appendix A for the de- See online Appendix A for the de-
tailed search strategy.
We  identified  grey  literature  (literature  that  is  not 
commercially published) by searching the websites of 
health technology assessment and related agencies and 
their associated databases, the websites of the manufac-
turers  of  IVIg  products  (Talecris  Biotherapeutics  and 
Baxter) and clinical trial registers. We also searched the 
websites of professional associations such as the Amer-
ican Society of Hematology, the European Hematology 
Association, the American Academy of Neurology, the 
American Neurological Association and the Canadian 
Neurological Sciences Federation for relevant evidence 
(including conference abstracts from 2007 and 2008, 
if available). We used Google and AlltheWeb search en-
gines to search for additional web-based materials and 
information.  We  supplemented  these  searches  by  re-
viewing the bibliographies and abstracts of key papers 
and conference proceedings. 
Ovid and PubMed AutoAlerts were set up to send bi-
weekly updates with any new literature, with the last 
automatic updates received on 1 Nov. 2008. We updated 
our searches of The Cochrane Library quarterly, with 
the last update search performed on 8 Oct. 2008 (Issue 
4, 2008).
We  also  requested  information  directly  from  the 
manufacturers of IVIg, Talecris Biopharmaceutics and 
Baxter (see online Appendix B).
Study  selection  and  assessment  of  methodological 
quality. Studies selected for inclusion met the follow-
ing criteria: trial was an RCT; participants had defin-
ite or probable CIDP; trial compared any dose of IVIg 
with  placebo,  corticosteroid  or  plasma  exchange;  and 
trial reported a change from baseline in both a disability 
score and an electrophysiological outcome (e.g., conduc-
tion velocity, latency, muscle or nerve action potential). 
There was no a priori selection of disability scales or 
electrophysiological outcomes. 
One  reviewer  (KG)  independently  extracted  data 
from  each  study,  and  these  data  were  subsequently 
verified by another reviewer (GB). The information ex-
tracted included population characteristics at baseline 
(e.g., mean age), as well as study characteristics such as 
drug interventions (including dose and dosing regimen), 
timing of assessment and adverse events (see online Ap-
pendix C). The reviewers were not blinded to the study 
authors’ names or funding sources. Any discrepancies 
were resolved by discussion. 
We used the Jadad scale17 to assess study quality, and 
we used the Schultz treatment allocation concealment 
questionnaire18  to  rate  allocation  concealment  as  ad-
equate, inadequate or unclear (see online Appendix D).
Data  synthesis  and  analysis.  We  described  all  trials 
qualitatively and did not include in the pooled data re-
sults from studies with poor quality (Jadad score of 2 or 
less). Studies that had Jadad scores of 3 or more and that 
reported the mean change (and standard deviation [SD]) 
from baseline for the disability outcomes were pooled to 
estimate the effect size of IVIg treatment. For continuous 
outcomes, we calculated the difference between study 
arms and 95% confidence intervals (CIs), using Review 
Manager (RevMan), version 5 (The Cochrane Collabora-
tion, Copenhagen, Denmark). The meta-analyses were 
based on the random-effects model of DerSimonian and 
Laird.19 For the aggregated continuous outcomes, we cal-
culated standardized mean differences with 95% CIs. We 
used a conservative approach when combining results 
from  crossover  and  parallel  trials,  with  only  the  data 
from the first arm of a crossover trial being included. 
For  binary  outcomes,  we  calculated  a  risk  ratio  and 
95% CI for each individual study, also using RevMan. A 
pooled risk ratio estimate of greater than 1 indicates that 
more patients in the IVIg arm relative to the control or 
comparator arm had a favourable outcome.
Sensitivity analyses were planned to examine wheth-
er the effect of IVIg varied with trial design or quality 
(e.g., comparison of those with and without adequate al-
location concealment). Subgroup analyses were planned 
to examine if the effect of IVIg differed depending on 
the duration or dose of IVIg treatment or the subtypes 
of CIDP (e.g., pure motor variant). We did not consider 
differences between various IVIg preparations. 
Results  
Studies  included  in  analysis.  Together,  the  original 
search and the updated search identified a total of 495 
citations, of which 325 were excluded after level 1 screen-
ing (citation, title and abstract, if available). An addi-
tional 11 citations were added from other sources, and 
181  citations  were  subjected  to  full-text  screening.  Of 
these, 19 publications were identified as potentially rel-
evant.10,13,20–36 A total of 8 articles were excluded, 2 be-
cause they were not RCTs;22,35 1 (an RCT)26 because the 
study population included patients with multifocal mo-
tor neuropathy, and data for patients with CIDP were not 
reported separately; and 520,23,25,29,31 because they were 
not full study reports (i.e., abstracts or conference pro-
ceedings only), and the corresponding full articles were included for data abstraction.13,28,30 Thus, 11 relevant full-
text records reporting 9 unique RCTs,10,13,21,24,27,28,30,32–34,36 
including 2 abstracts reporting outcomes that were not 
reported in the corresponding published RCT,10,21 were 
retained. 
A modified PRISMA flow diagram is presented in Fig. 1, 
and a list of the excluded studies appears in Appendix E. 
The 9 RCTs included a total of 312 patients with CIDP 
(Table 1). Of the 9 trials, 3 compared IVIg therapy with 
an  active  comparator  (plasma  exchange,24  plasma  ex-
change  using  extracorporeal  immunoadsorption,36  or 
oral prednisolone27), and the other 6 trials had placebo 
controls.13,28,30,32–34 Because of the small number of stud-
ies, we could not use funnel plots to assess publication 
bias. Typically, the minimum number of studies required 
to properly assess publication bias with funnel plots is 
suggested to be 10.45
Study  characteristics.  Three  of  the 
studies13,30,32 used the American Acad-
emy  of  Neurology  criteria  to  confirm 
the diagnosis of CIDP,44 and 2 of the 
studies27,28 used the inflammatory neur-
opathy  cause  and  treatment  (INCAT) 
criteria.27  The  other  4  studies24,33,34,36 
used  symptomatology  and  electro-
physiological testing (nerve conduction 
velocities and conduction blocks) as the 
criteria for diagnosis. The intervention 
periods for the trials were 6 months or 
less. 
All 6 crossover trials13,24,27,28,32,33 had 
a  conditional  crossover  depending 
upon the patient’s response to the first 
treatment:  patients  with  a  response 
to treatment did not cross over to the 
second  treatment  until  they  experi-
enced  deterioration  in  their  disease. 
Washout  periods  were  fixed  in  3  of 
the trials at 8 days,33 4 weeks32 and 6 
weeks,24  with  the  remaining  3  trials 
allowing  patients  with  deterioration 
to cross over to the second treatment 
early.13,27,28
A  variety  of  disability  scales  and 
electrophysiological  parameters  were 
reported as outcomes (see Table 1 for 
details). Six of the trials13,28,32–34,36 used 
a response to treatment as an outcome; 
however,  the  criteria  used  to  define 
improvements varied across trials. 
IVIg  versus  active  comparator. Prednisolone was the 
active comparator in one randomized crossover trial.27 
This study compared IVIg 1.0 g/kg given on 2 consecu-
tive  days  (or  2.0  g/kg  delivered  in  24  hours)  with  a 
6-week course of oral prednisolone, with an initial dose 
of 60 mg/d for 2 weeks, tapered to 10 mg/d over 4 weeks. 
The trial had a Jadad score of 5 and was stopped early 
because the study medication expired. Thirty-two pa-
tients had been randomly assigned to treatment, all of 
whom completed the first treatment period. Only 25 pa-
tients were crossed over to the second treatment period, 
24 of whom completed both treatment periods. Six pa-
tients who were initially assigned to receive IVIg ther-
apy did not continue for the following reasons: further 
treatment deemed unnecessary (3 patients), withdrawal 
from study because of worsening symptoms (2 patients, 
who went on to receive open-label IVIg) and discovery 
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Included in clinical review
n = 11 citations
(n = 9 studies)
Potentially relevant reports 
retrieved for scrutiny
n = 324
      
       Excluded   n = 170
•  Not an RCT   n = 107 
•  No outcomes reported   n = 14
•  Language other than English   n = 12 
•  Review (other than narrative review)   n = 10 
•  Narrative review   n = 10
•  Abstract or registry report of included RCT   n = 8
•  Guideline or commentary   n = 4 
•  Not full study report   n = 3 
•  Not dealing with disease of interest   n = 2
Excluded   n = 325   
Citations identi￿  ed from electronic 
search and screened
  n = 495
Identi￿  ed from other 
sources    n = 11
Figure 1. Flow diagram for reports selected for clinical review. 
RCT = randomized controlled trialResearch                                                                                                                                    Gaebel et al.
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Table 1:  Study characteristics
Study
Patients
Comparison Outcomes Quality* Notes Total IVIg C
Vermeulen 199334 28† 15 13 0.4 g/kg daily x 5 d 
v. placebo (albumin 
3 g/50 mL)
MRC-SS, RS, CMAP, 
NCV (16 electro
physiological 
measures in total)
5, A Patients previously treated with immuno-
supressants excluded; minimum disability score 
required for inclusion; prede￿  nition of response 
to therapy
Mendell 200130 53 30 23 1.0 g/kg daily x 2 d, 
then again on d 21 
v. placebo (albumin)
AMS, HFDS, NCS 5, A No immunotherapy for any indication in 
previous 3 mo
Single-blind parallel
Zinman 200536 18 13 
(of whom
 4 were 
excluded 
from 
analysis)§
5 1 g/kg daily x 2 d 
for 6 mo v. plasma 
exchange (3 txs over 
7 d for 6 mo
AMS, TCNS, HFDS, 
NCV, CMAP, F-wave 
latencies
2, I Patients previously treated with IVIg or plasma 
exchange excluded; no immunosuppressant 
therapy in previous 6 mo; prede￿  nition of 
response to therapy
Single-blind crossover
Dyck 199424 20 15 17 0.4 g/kg per wk x 3 
wk followed by 0.2 
g/kg per wk x 3 wk 
v. plasma exchange 
twice wkly x 3 wk 
followed by once 
wkly x 3 wk
NDS, NDS-W, ∑CMAP, 
SNAP, VDT great toe
1, I No plasma exchange or IVIg in previous 6 wk; 
minimum disability score required for inclusion; 
￿  xed washout period
Double-blind crossover
Hughes 200127 32‡ 24 24 1.0 g/kg daily x 2 d 
or 2.0 g/kg over 24 
h v. oral predniso-
lone, 60 mg/d x 2 
wk, then tapered
INCAT disability scale, 
10-m walk, 9-hole 
peg test, MRC-SS, 
GS, RHS, RS, SF-36 
physical function 
score, SSS
5, A No immunosuppressants in previous 6 wk; 
stable AZA dose allowed; prede￿  ned rules for 
washout period, prede￿  nition of response to 
therapy
Hughes 200828 117‡ 59 58 2.0 g/kg over 2–4 
d followed by 1 
g/kg over 1–2 d 
every 3 wk for 24 
wk v. placebo (0.1% 
albumin) 
INCAT disability score, 
GS, MRC-SS, time to 
relapse for patients 
with response in ￿  rst 
period, INCAT SS, 
CMAP
4, U No steroids, IVIg or plasma exchange in 
previous 3 mo; no immunomodulatory or 
immunosuppressive agents in previous 6 mo; 
minimum disability score required for inclusion; 
prede￿  ned rules for washout period; 
prede￿  nition of response to therapy
Hahn 199613 30† 25 25 0.4 g/kg daily x 5 
d v. placebo (10% 
dextrose)
NDS, CG, GS, MCV, 
distal motor laten-
cies, CMAP
4, A Patients with previous exposure to IVIg 
excluded; low dose prednisone (< 20 mg/day) 
allowed if treatment initiated > 3 mo before; 
minimum disability score required for inclusion; 
prede￿  ned rules for washout period; 
prede￿  nition of response to therapy
Thompson 199632 7†   7 7 0.4 g/kg daily x 5 d 
v. placebo (albumin)
Ambulation index, 
10-m walk time, E- 
MRC-SS, 9-hole peg 
test, myometer score, 
HMAS, CMAP distal 
motor latency, MCV, 
F-wave latency 
4, A Patients with previous exposure to IVIg 
excluded; ￿  xed washout period; prede￿  nition 
of response to therapy
van Doorn 199033 7   7 7 0.4 g/kg daily x 5 d 
v. placebo (3 g/50 
mL 20% albumin)
RS, CMAP, NCV, mean 
time to clinical dete-
rioration 
4, A Previous response to IVIg treatment required for 
inclusion; ￿  xed washout period; prede￿  nition of 
response to therapy
AMS = average muscle strength (modi￿  ed Medical Research Council),30 AZA = azathioprine, C = control, CG = clinical grade, CMAP = compound muscle action 
potential, E-MRC-SS = expanded Medical Research Council sum score, GS = grip strength, HFDS = Hughes functional disability scale,37 HMAS = Hammersmith motor 
ability score,38 INCAT = in¨  ammatory neuropathy cause and treatment,27 INCAT SS = INCAT sensory score, IVIg = intravenous immunoglobulin, MCV = motor 
conduction velocity, MRC-SS = Medical Research Council sum score,39 NCS = nerve conduction study, NCV = nerve conduction velocity, NDS = neurological disability 
score,40 NDS-W = neurological disability score weakness subscore,40 RHS = Rotterdam handicap scale,41 RS = Rankin scale,42 SF-36 = medical outcome study 36-item 
short-form health status scale,43 SNAP = sensory nerve action potential, SSS = sensory sum score, TCNS = Toronto clinical neuropathy score,36 txs = treatments, 
VDT = vibratory detection threshold
* Quality assessed using Jadad scale17 (numeric value) and Schultz treatment allocation concealment questionnaire18 (where A = adequate, I = inadequate, and 
   U = unclear)
† Diagnosis according to criteria of American Academy of Neurology44
‡ Diagnosis according to the INCAT criteria27
§ One intervention arm, with 4 patients, used a low dose of IVIg (0.5 g/kg daily), but 2 of the patients died of unrelated causes, and the remaining 2 patients were 
    therefore excluded from the analysisof a small-cell carcinoma (1 patient). Two patients who 
received  prednisolone  first  did  not  continue  with  the 
second treatment period: 1 had psychosis, and the other 
preferred not to start the second treatment.
The primary outcome in this study was the change in 
INCAT disability score27 at 2 weeks, relative to baseline. 
For all patients who completed both arms of the trial, the 
INCAT disability score improved from baseline, but there 
were no significant differences between treatment arms 
in the extent of improvement. There were also no differ-
ences between treatments for any of the secondary out-
comes: Medical Research Council (MRC) sum scores (for 
muscle strength),39 grip strength, 10-metre walk time, 
9-hole peg test, modified Rankin scale score,42 Rotter-
dam Handicap Score,41 medical outcomes study short-
form 3643 or any of the electrophysiological measures.
The incidence of total adverse events was similar be-
tween  the  2  treatments.  Three  serious  adverse  events 
causing  the  patients’  withdrawal  from  the  study  were 
reported:  carcinoma  and  psychosis  with  prednisolone 
treatment and heart failure with IVIg therapy. 
Plasma  exchange  was  the  active  comparator  in  an-
other randomized crossover trial.24 That study compared 
IVIg 0.4 g/kg once a week for 3 weeks followed by 0.2 g/
kg once a week for 3 weeks with plasma exchange twice 
a week for 3 weeks followed by plasma exchange weekly 
for 3 weeks. The quality of the trial was low (Jadad score 
1). Twenty patients were enrolled, 19 of whom completed 
the first treatment period and 13 of whom completed the 
second treatment period. Of the 6 patients who com-
pleted the first treatment but did not receive the second 
treatment, 2 withdrew to undergo treatment elsewhere 
and 4 did not require the second treatment.
The primary outcomes were changes after 6 weeks in 
the neurological disability score (NDS),40 NDS weakness 
subscore and summed compound muscle action poten-
tial (∑CMAP) of the ulnar, median and peroneal nerves. 
There  were  no  significant  differences  between  the  2 
treatment groups. There was also no significant differ-
ence  between  treatment  arms  for  the  secondary  out-
comes of summed sensory nerve action potential of the 
median and sural nerves or vibratory detection thresh-
old of the great toe.
Total and serious adverse events were not reported, 
and there was 1 withdrawal due to an adverse event, an 
infection  associated  with  an  indwelling  catheter  in  a 
patient who underwent plasma exchange. Lightheaded-
ness, rash and nausea were reported as adverse events, 
but their frequency was not reported.
Plasma exchange was also studied in a randomized, 
3-arm parallel group trial36 that compared IVIg 1 g/kg 
daily for 2 consecutive days, 0.5 g/kg daily for 2 consecu-
tive days, and 3 plasma exchange treatments with spe-
cial staphylococcal protein immunoadsorption columns 
(Excorim, Lund, Sweden) over 7 days. The quality of this 
trial was also low (Jadad score 2). Twenty patients were 
enrolled, and 18 received treatment before the study was 
halted because of cessation of funding. Nine patients re-
ceived the higher-dose IVIg, 4 received the lower-dose 
IVIg,  and  5  underwent  plasma  exchange.  Two  of  the 
patients in the lower-dose IVIg treatment arm died of 
illnesses unrelated to their treatment (pneumonia and 
sepsis  for  one,  congestive  heart  failure  for  the  other), 
which left only 2 patients in that arm. Because of this 
small sample size, the data for lower-dose IVIg were not 
included in the final analysis. Therefore, the final analy-
sis consisted of data for 9 patients who received IVIg and 
5 who underwent plasma exchange.
The primary outcome measure was a determination 
of patients with a clinical response to treatment. As de-
fined  by  the  authors,  a  patient  with  clinical  response 
showed improvement in 2 of 4 measures (average muscle 
strength,30  grip  strength,  Toronto  clinical  neuropathy 
score36 and Hughes functional disability score37) with-
out deterioration in the other measures. However, the 
authors did not specify the criteria for improvement for 
each of these assessment scales. There was no significant 
difference in the proportion of patients with a clinical 
response between the 2 treatment groups. At 2 months, 
50% of patients in the IVIg group and 80% of those in the 
plasma exchange group were considered to have a clin-
ical response (p = 0.56). There were no significant dif-
ferences between the treatment groups in terms of nerve 
conduction changes, even though the conduction velocity 
in sensory nerves, CMAP and F-wave latencies improved 
numerically with plasma exchange and worsened with 
IVIg therapy.
Two serious adverse events were reported in the IVIg 
treatment arm (heart failure and pneumonia with sep-
sis, both resulting in death). The authors deemed both 
deaths to be unrelated to the treatment. Two withdrawals 
due to adverse events (a rash in both cases) were also re-
ported for the IVIg group.
IVIg versus placebo. All 6 of the randomized, placebo-
controlled trials13,28,30,32–34 were of good quality, with Ja-
dad scores of 4 or higher, and all but 128 had adequate 
concealment.  Two  studies  used  a  parallel  group  de-
sign,30,34 and 4 studies used a crossover design.13,28,32,33
In 1 of the 2 studies with parallel group design, Ver-
meulen and colleagues34 randomly assigned 15 patients 
to receive 0.4 g/kg IVIg for 5 consecutive days and 13 
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final assessment between 16 and 21 days after receiving 
the trial treatments. To be eligible for inclusion, patients 
had to have a disability of at least 3 on the modified 
Rankin scale.42 The primary outcome, the proportion of 
patients showing an improvement of 1 point or greater 
on the Rankin scale, was similar between the 2 treat-
ment groups (26.7% for IVIg group v. 23.0% for placebo 
group). The mean improvement in the MRC sum score 
was also similar for the 2 groups (mean [SD] 1.60 [SD 
3.04] for IVIg group v. 1.23 [SD 3.2] for placebo group). 
The  authors  reported  significant  improvements  after 
IVIg  therapy  for  only  3  of  the  16  electrophysiological 
measures recorded: ulnar distal latency (p = 0.005), tib-
ial distal CMAP (p = 0.003) and peroneal nerve conduc-
tion velocity (p = 0.003). The authors did not comment 
on adverse events for this trial.34
The  second  trial  with  parallel  group  design30  com-
pared IVIg (1 g/kg given on 2 consecutive days with a 
third dose on day 21) with placebo. Thirty patients were 
randomly assigned to IVIg therapy, and 29 completed 
the final assessment at day 42. A single patient was ex-
cluded because of incomplete data collection at the insti-
tutional study site. Of the 23 patients randomly assigned 
to receive placebo, 2 dropped out (because of urticaria 
and patient choice to quit), and 21 completed the final 
assessment at day 42. The primary outcome was muscle 
strength as measured with a modified MRC scale,39 re-
ferred to as average muscle strength. The average muscle 
strength improved significantly with IVIg therapy (mean 
difference  0.44,  standard  error  0.21,  p  =  0.045).  The 
percentage of patients with an improvement of at least 
1 grade in the Hughes functional disability score was 
significantly larger for the IVIg group (34.0% v. 9.5%, 
p = 0.019). The groups did not differ in terms of motor 
nerve conduction studies on the median, ulnar, pero-
neal and tibial nerves. There were no serious adverse 
events and only 1 withdrawal due to an adverse event in 
the IVIg group. Higher proportions of patients receiving 
IVIg experienced the common adverse events of head-
ache, nausea, chills and fever, and comparable propor-
tions of the two treatment groups experienced transient 
hypotension.30 
In 1 of the 4 crossover trials comparing IVIg with pla-
cebo, Hughes and colleagues28 compared a loading dose 
of IVIg (2.0 g/kg) given over 2–4 days, followed by 1.0 g/
kg over 1–2 days given every 3 weeks for 24 weeks with 
placebo. The study design allowed patients with no re-
sponse (where response was defined as an improvement 
of 1 point or more on the adjusted INCAT scale) to cross 
over to the second treatment any time after week 6. All 
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of the patients who had a response were randomly re-
assigned at the end of 24 weeks to either IVIg or placebo 
in a parallel group design.
Of 59 patients initially randomly assigned to receive 
IVIg, 3 withdrew (because of an adverse event, with-
drawal of consent and a protocol violation, respectively), 
23 were deemed to have no response and crossed over to 
placebo, and 33 completed the 24 weeks of therapy. Of 
the 23 who crossed over to placebo, 16 had no response, 
2 withdrew their consent, and 5 had a response. Of 58 
patients initially randomly assigned to receive placebo, 
1 withdrew because of an adverse event, 45 had no re-
sponse and crossed over to IVIg therapy, and 12 complet-
ed the 24-week trial. Of the 45 patients who crossed over 
to IVIg treatment, 16 had no response, 2 experienced an 
adverse event, 1 was lost to follow-up, and 26 completed 
the  24-week  trial.  The  IVIg  group  had  a  significantly 
larger proportion of patients with response than did the 
placebo group (54% v. 21%, p = 0.0002). 
There  was  also  significantly  greater  improvement 
after IVIg therapy than placebo therapy in grip strength 
(improvement of 13.2 [SD 19.3] v. 1.5 [SD 15.6] points, 
respectively;  p  =  0.0008)  and  the  MRC  sum  score 
(improvement of 3.3 [SD 5.6] v. 0.2 [SD 4.5] points, re-
spectively;  p  =  0.001).  The  probability  of  relapse  was 
lower among patients who were randomly reassigned to 
IVIg than among those randomly reassigned to placebo 
(13% v. 45%), and the time to relapse was significantly 
longer for patients who received IVIg than for those who 
received placebo (p = 0.011). Results not reported in this 
original paper were reported in 2 abstracts presented at 
meetings of the American Academy of Neurology and 
the American Neurological Association in 2008. Merkies 
and colleagues10 reported significant improvement (by 
3.4 points) in the 36-item short-form health status scale 
(physical component summary score) after IVIg therapy 
(p = 0.001). Bril and colleagues21 reported a nonsignifi-
cant trend favouring IVIg in all of the electrophysiologic-
al measures.
In another crossover study, Hahn and colleagues13 as-
signed 16 patients to receive IVIg 0.4 g/kg for 5 consecu-
tive days and 14 patients to receive placebo treatment 
for 5 consecutive days, with a 28-day follow-up period. 
Patients who experienced a deterioration of more than 
20 points in the NDS were allowed to cross over to the 
second treatment at day 21. A response was predefined as 
a change in the NDS of 20 points or more or improvement 
by 1 clinical grade or more. Both NDS and CIDP clinical 
grade improved significantly after treatment with IVIg 
(p < 0.002 and p < 0.005, respectively). The authors also 
reported a significant improvement in grip strength after Research                                                                                                                                    Gaebel et al.
treatment with IVIg compared with placebo (6.3 [SD 1.7] 
v. –0.8 [SD 0.9], respectively; p < 0.005). 
There was also significantly greater improvement in 
the following electrophysiological outcomes after IVIg 
therapy relative to placebo therapy: summed motor con-
duction velocity 15.3 (SD 44.1) v. –13.2 (SD 39.9) points 
(p < 0.0001) and summed distal motor latency 3.9 (SD 
14.5) v. –1.2 (SD 15.4) points (p < 0.04).13 
In these 2 trials,13,28 a total of 15 patients experienced 
a serious adverse event (1 of those receiving IVIg in the 
trial by Hahn and colleagues;13 6 of those receiving IVIg 
and 8 of those receiving placebo in the trial by Hughes 
and colleagues28). Hahn and colleagues13 reported that 
one  patient  had  symptoms  resembling  aseptic  menin-
gitis after IVIg therapy, but the patient continued with 
treatments. Hughes and colleagues28 reported common 
adverse events of headache (4.0% in IVIg group v. 1.2% 
in placebo group) and pyrexia (2.4% in IVIg group v. 0% 
in placebo group), with the data reported as percentages 
of infusions not patients. Hughes and colleagues28 re-
ported only 1 withdrawal due to an adverse event. The 
patient withdrew because of lack of efficacy and subse-
quently died of sepsis.
An additional 2 placebo-controlled crossover trials32,33 
each had 7 patients. In both trials, the patients were as-
signed to receive IVIg 0.4 g/kg for 5 consecutive days or 
placebo. In 1 of these studies,32 the investigators judged 
the patients’ response after 28 days, and those with no 
response crossed over to the second treatment. For pa-
tients with a response, the second treatment was with-
held until the patient required further treatment. The 
authors defined a response as at least 3 of the following: 
improvement of at least 1 grade in the ambulation index, 
improvement of more than 2 seconds in 10-metre walk 
time, improvement of 4 or more units in the expanded 
MRC sum score, improvement of more than 3 seconds in 
time for the 9-hole peg test, improvement of 10% or more 
in mean myometer score for 2 individual muscle groups, 
and improvement of at least 2 points on the Hammer-
smith motor ability score. Thompson and colleagues32 
had assigned 4 patients to IVIg treatment and 3 patients 
to placebo (with both groups crossing over to the second 
treatment, either IVIG or placebo) by the time the trial by 
Hahn and colleagues,13 described above, was published, 
at which point Thompson and colleagues stopped their 
trial. They reported that 43% of the 7 patients showed 
improvement in 3 of the 6 outcome measures.
In  the  other  small  crossover  trial,  Van  Doorn  and 
colleagues33 investigated the time to deterioration after 
IVIg  therapy  was  stopped.  Seven  patients  who  had 
previously  been  receiving  IVIg  therapy  stopped  their 
treatments and were randomly assigned to receive 5 days 
of treatment with IVIg (0.4 g/kg) or placebo. All patients 
were seen at regular intervals. When a deterioration of 
at least 1 point on the Rankin scale was detected for a 
patient, he or she received the first assigned treatment. 
If by day 8 after treatment the patient’s condition was 
still deteriorating, the second (crossover) treatment was 
given. If there was no deterioration, the second treat-
ment was withheld until deemed necessary. Van Doorn 
and colleagues33 reported a significantly greater time to 
deterioration with IVIg therapy than with placebo (6.4 
[SD 3.0] weeks v. 1.3 [SD 1.3] weeks, p = 0.02). A signifi-
cantly greater time to deterioration was also reported by 
Hughes and colleagues28 during the extension phase of 
their trial (for patients with a response to treatment) (p = 
0.01). Neither Thompson and colleagues32 nor Van Doorn 
and colleagues33 reported significant changes in electro-
physiological parameters. No patients experienced side 
effects in the trial by van Doorn and colleagues,33 and 
adverse  events  were  not  reported  by  Thompson  and 
colleagues.32
We  included  data  from  413,28,30,34  of  the  6  placebo-
controlled  trials  described  above  in  a  meta-analysis. 
These 4 trials reported changes from baseline in a dis-
ability score (i.e., a scale that measured muscle strength 
or weakness). The meta-analysis revealed a significant 
treatment effect, with a standardized mean difference of 
0.65 (95% CI 0.23 to 1.08) in favour of IVIg (Fig. 2). A 
pooled analysis of the proportion of patients with a re-
sponse to treatment, as defined by the investigators of 
each of the trials, resulted in a risk ratio of 2.74 (95% CI 
1.80 to 4.16) in favour of IVIg (Fig. 3).
Sensitivity  analysis. Given the small number of trials 
identified,  the  variety  of  comparators,  the  variety  of 
doses and administration regimens for IVIg and the var-
iety of outcome measures used by the original investiga-
tors, we did not perform any sensitivity analyses.
Interpretation
We identified 9 RCTs providing evidence related to IVIg 
treatment for patients with CIDP. All used short interven-
tion periods (8 days to 6 months), and the total sample size 
was 312 patients. Each active comparator and IVIg pro-
duced similar improvements from baseline, but there was 
no incremental benefit in the primary outcomes in com-
parisons between IVIg therapy and an active comparator. 
Five of the 6 placebo-controlled trials showed that IVIg 
therapy was superior to placebo on the basis of a variety 
of disability or impairment outcomes (in terms of greater 
proportion  of  patients  with  a  response,28,30  significant 
Open Medicine 2010;4(3):e161improvement13,33 or numerically greater improvement32). 
Only 3 trials13,28,34 demonstrated a significantly greater 
improvement in any of the electrophysiological param-
eters with IVIg therapy compared with placebo.
A total of 14 different disability or impairment scales 
were used across the 9 trials. Some scales emphasized 
mobility, providing little information about arm func-
tion  (e.g.,  Hughes  functional  disability  score,  Rankin 
scale), whereas the INCAT sensory score combined both 
arm and leg functionality. Scales providing measures of 
muscle strength were reported as a summed score (e.g., 
MRC sum score) or as individual muscle strength scores, 
whereas others provided a measure of muscle weakness 
(e.g., NDS weakness subscore). Electrophysiological out-
comes were also reported as either single-nerve conduc-
tion velocities or compound action potentials for single 
muscles or as summed velocities or action potentials of 
many nerves and muscles. 
The definition of clinical response was not standard-
ized across the trials. Four trials defined a response as an 
improvement based on a single scale,13,24,28,30 and 2 trials 
defined a response as improvement in 2 of 4 measures36 
or 3 of 6 measures.32 The proportion of patients with a 
response ranged from 27% to 64% across these trials.
The variety of trial designs, especially crossover trials 
without  a  fixed  wash-out  period,  and  the  presence  of 
trials  allowing  the  use  of  concomitant  therapies  and 
others not allowing their use, contributed to the incon-
sistent  treatment  effect  sizes  reported.  The  variety  of 
outcome measures used across the trials (as described 
above) was also a contributing factor. Some of this in-
consistency may also have been due to the populations 
included in the trials: patients with a known response to 
IVIg versus previously untreated patients and patients 
with different courses of the disease. 
Even with these study limitations, IVIg therapy im-
proved disability and impairment significantly relative 
to placebo over the short term (6 months or less) and 
provided clinical benefits similar to those realized with 
plasma  exchange  and  oral  prednisolone.  Our  findings 
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Figure 2. Forest plot showing the effect of intravenous immunoglobulin (IVIg) within each study and the overall pooled 
estimate, as standardized mean difference in disability score. CI = confidence interval, df = degrees of freedom, IV = inverse 
variance, IVIg = intravenous immunoglobulin, SD = standard deviation
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Figure 3. Forest plot for the pooled analysis of the proportion of patients with a response to treatment. CI = confidence 
interval, df = degrees of freedome, IVIg = intravenous immunoglobulinare consistent with a recent Cochrane systematic review 
of IVIg therapy for CIDP that was published after we 
had submitted a copy of our final report46 to the fund-
ing  agency  (CADTH).  In  that  review,47  Eftimov  and 
colleagues asked original authors for their data and con-
tacted investigators in the field to identify unpublished 
or  overlooked  studies,  neither  of  which  we  did.  Their 
primary  outcome  measure  was  a  change  in  disability 
according to the Rankin scale. If a particular study had 
not used this disability scale, the authors transformed 
the data to fit the Rankin scale. They also excluded 2 
trials33,36 that we included in our review; however, we did 
not pool the data from either of these 2 studies. Eftimov 
and colleagues47 concluded that IVIg improves disabil-
ity relative to placebo, and their reported standardized 
mean  difference  in  disability  scores  of  0.54  (95%  CI 
0.24 to 0.84) is comparable to our pooled standardized 
mean difference of 0.65 (95% CI 0.23 to 1.08). If we had 
excluded from our meta-analysis another trial that Eft-
imov and colleagues also excluded,13 then our point esti-
mate would have been 0.53 (95% CI 0.24 to 0.82), even 
closer to theirs. Even though the study by Hahn and col-
leagues13 was a crossover trial, we used data from the 
first treatment arm in our meta-analysis. Eftimov and 
colleagues47 also reported a number needed to treat of 3, 
but we did not perform that type of analysis.
Because of the small sample sizes and the short dur-
ations of the trials included in our review, rare but ser-
ious adverse events were not observed. However, case 
reports describing stroke after administration of IVIg 
have been published.48–50 
An  observational  study,22  which  we  did  not  include 
in our meta-analysis, looked at the 10-year safety of the 
IVIg  preparation  Octagam  (Octapharma  Canada  Inc., 
Scarborough ON), which was very recently licensed for 
sale in Canada. This prospective cohort enrolled a total 
of 6357 patients, of whom 1093 patients were using the 
IVIg preparation for treatment of an autoimmune disease. 
Among these 1093 patients were 36 patients with CIDP 
who underwent a total of 719 IVIg infusions, and 3 (8%) of 
these patients reported an adverse event. The most com-
mon adverse events reported for patients with an auto-
immune disease, in descending order of frequency, were 
headache, flushing, fatigue and nausea. The authors con-
cluded that this IVIg preparation was well tolerated in rou-
tine daily use, with an overall adverse event rate of 4.2% of 
all patients and 0.35% of all infusions. The vast majority 
of adverse events were classified as nonserious (94.8%) 
and of mild (55.9%) or moderate (34.3%) intensity.
Because of the short intervention periods, the long-
term effects of IVIg could not be ascertained from the 
trials included in our review. In a chart review of neuro-
physiological data for 11 patients with CIDP, Vucic and 
colleagues35 reported that long-term IVIg treatment re-
sulted in reversal of conduction block, improvement in 
distal amplitudes of CMAP and sensory nerve action po-
tential, and reduction in spontaneous activity indicative 
of ongoing denervation. 
IVIg  does  not  work  for  all  patients:  in  this  review, 
the proportion of patients with a response to IVIg was 
less than 65%. Even with significant improvements in 
disability and impairment, patients remain dependent 
on IVIg, and new conduction blocks may develop while 
they are receiving treatment. As such, there is a need for 
future clinical trials to investigate immunosuppressant 
therapies (e.g., novel and older agents, higher doses than 
previously used) alone or in combination with IVIg to de-
termine if there is some other approach that will reliably 
induce remission in patients with CIDP. A very recently 
published RCT51 investigated the addition of methotrex-
ate 7.5 mg weekly to the existing treatment regimens of 
patients  with  CIDP.  After  40  weeks  of  treatment,  the 
methotrexate had no significant benefit relative to pla-
cebo. The authors stated that the negative trial results 
might have been due to study limitations and suggested 
that  a  different  dose  of  methotrexate  might  have  had 
more favourable results.
One or 2 outcome measures should be identified as the 
standard outcomes to be used in future CIDP research, 
which  would  facilitate  comparisons  across  treatment 
regimens. This may assist in identifying a truly superior 
therapeutic regimen for the management of this disease.
As part of our original review,46 we performed an eco-
nomic review and primary economic analysis. The latter 
was a cost–utility primary economic analysis, from the 
perspective of a publicly funded health care system using 
a Markov model of adult patients with CIDP (weighing 
75 kg). The treatment comparators were IVIg and oral 
corticosteroids, and the time horizon was 5 years. Tak-
ing into account both the gain in utility from IVIg treat-
ment and the disutility from adverse events, we found 
that patients in the IVIg treatment arm had 0.187 more 
quality-adjusted  life  years  (QALYs)  than  those  in  the 
corticosteroid arm. The resulting incremental cost–util-
ity ratio of IVIg compared with corticosteroids was $549 
449 per QALY gained. The incremental cost–utility ratio 
varied with patient weight, from $262 260 for a 35-kg 
patient to $694 933 for a 95-kg patient.
Conclusions
In statistical terms, IVIg therapy is superior to placebo 
in reducing the disability and impairment experienced 
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this therapy is significantly lower, and the time to deteri-
oration significantly greater. The effectiveness of IVIg is 
similar to that of the alternative treatment strategies of 
plasma exchange and oral prednisolone. Given concerns 
about adverse events associated with long-term cortico-
steroid use, and the cost of and limited access to plasma 
exchange, IVIg may be suitable for patients who cannot 
tolerate  or  access  the  alternative  therapies,  provided 
society is willing to pay the financial cost of more than 
$200 000 per QALY.
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